- Report
- August 2023
- 113 Pages
Global
From €4397EUR$4,500USD£3,671GBP
- Report
- April 2023
- 117 Pages
Global
From €4641EUR$4,750USD£3,874GBP
- Report
- January 2022
- 121 Pages
Global
From €4641EUR$4,750USD£3,874GBP
- Report
- April 2023
- 450 Pages
Global
From €2223EUR$2,275USD£1,856GBP
€3175EUR$3,250USD£2,651GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1881EUR$1,925USD£1,570GBP
€2687EUR$2,750USD£2,243GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2223EUR$2,275USD£1,856GBP
€3175EUR$3,250USD£2,651GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2223EUR$2,275USD£1,856GBP
€3175EUR$3,250USD£2,651GBP
- Report
- August 2022
- 285 Pages
Global
From €6497EUR$6,650USD£5,424GBP
€9282EUR$9,500USD£7,749GBP
- Report
- August 2022
- 142 Pages
Global
From €3249EUR$3,325USD£2,712GBP
€4641EUR$4,750USD£3,874GBP
- Report
- January 2022
- 125 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Report
- January 2022
- 200 Pages
Global
From €5130EUR$5,250USD£4,282GBP
€7328EUR$7,500USD£6,118GBP
- Report
- January 2022
- 200 Pages
Global
From €5130EUR$5,250USD£4,282GBP
€7328EUR$7,500USD£6,118GBP
- Report
- January 2022
- 60 Pages
Global
From €2702EUR$2,765USD£2,255GBP
€3859EUR$3,950USD£3,222GBP
- Report
- January 2022
- 60 Pages
Global
From €2702EUR$2,765USD£2,255GBP
€3859EUR$3,950USD£3,222GBP
- Report
- January 2022
- 60 Pages
Global
From €2702EUR$2,765USD£2,255GBP
€3859EUR$3,950USD£3,222GBP
- Report
- January 2022
- 60 Pages
Global
From €2702EUR$2,765USD£2,255GBP
€3859EUR$3,950USD£3,222GBP
- Report
- January 2022
- 60 Pages
Global
From €2702EUR$2,765USD£2,255GBP
€3859EUR$3,950USD£3,222GBP
- Drug Pipelines
- September 2021
- 60 Pages
Global
From €1026EUR$1,050USD£856GBP
€1466EUR$1,500USD£1,224GBP
- Report
- January 2022
- 115 Pages
Global
From €4641EUR$4,750USD£3,874GBP
- Report
- January 2022
- 100 Pages
Asia Pacific
From €4641EUR$4,750USD£3,874GBP
The Pancreatic Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat pancreatic cancer. Pancreatic cancer is a type of cancer that affects the pancreas, an organ located in the abdomen. It is a particularly aggressive form of cancer, and is often difficult to treat.
Pancreatic cancer drugs are designed to target the cancer cells and stop their growth. They can be used alone or in combination with other treatments, such as chemotherapy or radiation. Commonly used drugs include gemcitabine, capecitabine, and erlotinib.
The Pancreatic Cancer Drugs market is highly competitive, with many companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck, Pfizer, Roche, and Novartis. Show Less Read more